COVID-19对患有多发性硬化症的人的疾病活动,进展和认知表现没有影响:为期2年的研究
Federico Montini1, Agostino Nozzolillo1, Nicolò Tedone2,3
1Neurology Unit, IRCCS Ospedale San Raffaele, Milano, Italy.
Journal of neurology, neurosurgery, and psychiatry
|October 19, 2023
概括
在感染后18-24个月内,COVID-19感染并没有显著影响多发性硬化症 (MS) 患者的疾病活动或认知功能. 这项研究发现,在暴露于SARS-CoV-2后,MS患者的残疾恶化或神经心理困扰风险没有增加.
科学领域:
- 神经学 神经学
- 传染性疾病 传染性疾病
- 免疫学 免疫学 免疫学
背景情况:
- COVID-19对患有多发性硬化症 (MS) 的人的长期影响在很大程度上仍未被描述.
- 了解这些后果对于管理SARS-CoV-2感染后的MS患者护理至关重要.
研究的目的:
- 调查COVID-19和疾病活动,残疾进展,神经心理困扰和MS患者 (PwMS) 的认知功能之间的联系.
- 在18-24个月的时间内,比较PwMS中患有COVID-19 (MS-COVID) 和没有 (MS-NCOVID) 的患者的结果.
主要方法:
- 一项队列研究将174名有COVID-19病史的PwMS与348名没有COVID-19的PwMS进行了比较.
- 纵向评估包括临床数据,脑部MRI,SARS-CoV-2免疫反应和综合的神经心理测试.
主要成果:
- 在扩展残疾状况量表 (EDSS) 恶化,复发率或疾病修饰疗法的变化方面,没有观察到群体之间的显著差异.
- 大脑MRI显示,在MS-COVID和MS-NCOVID组中,新的T2损伤和加多增强损伤的发生率相似.
- 认知障碍和神经精神疾病的表现相似,SARS-CoV-2细胞免疫反应没有差异.
结论:
- 在感染后18-24个月内,COVID-19感染似乎不会对多发性硬化症患者的疾病活动,病程或认知表现产生负面影响.
- 这些发现表明,SARS-CoV-2感染不会改变多发性硬化症的长期发展轨迹.
相关概念视频
Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
Cognitive Development During Adulthood
125
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
125
Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
Parkinson's Disease: Overview
567
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
567
Negative and Cognitive Symptoms of Schizophrenia
50
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
50


